Biotin interference in routine IDS-iSYS immunoassays for aldosterone, renin, insulin-like growth factor 1, growth hormone and bone alkaline phosphatase

Author(s):  
Cindy Soendersoe Knudsen ◽  
Kasper Adelborg ◽  
Esben Søndergaard ◽  
Tina Parkner
2018 ◽  
Vol 65 (2) ◽  
Author(s):  
Ewelina Witkowska-Sędek ◽  
Anna Stelmaszczyk-Emmel ◽  
Anna Majcher ◽  
Urszula Demkow ◽  
Beata Pyrżak

The relationships between bone turnover, the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis and vitamin D are complex, but still not fully explained. The GH/IGF-1 axis and vitamin D could modulate their metabolism mutually and influence activation of cell proliferation, maturation, and mineralization as well as bone resorption. The aim of this study was to evaluate the reciprocal associations between bone formation markers [alkaline phosphatase (ALP), bone alkaline phosphatase (BALP)], the GH/IGF-1 axis and 25-hydroxyvitamin D [25(OH)D] in children with growth hormone deficiency at baseline and during recombinant human growth hormone (rhGH) therapy. ALP, BALP, 25(OH)D and IGF-1 concentrations were evaluated in 53 patients included in this prospective three-year study. ALP, BALP and IGF-1 increased during rhGH therapy. Baseline ALP correlated positively with baseline height velocity (HV). ALP and BALP at 12 months correlated positively with HV in the first year of therapy. We found positive correlations between ALP and IGF-1 at baseline and during the first year of therapy, between BALP at 12 months and rhGH dose in the first year of therapy, and between mean doses of cholecalciferol in the first year of rhGH therapy and early changes in BALP during rhGH therapy. Our results indicate that vitamin D supplementation enhances the effect of rhGH on bone formation activity, which could improve the effects of rhGH therapy. ALP and BALP are useful in early prediction of the effects of rhGH therapy, but their utility as long-term predictors is not sufficient. 


2011 ◽  
Vol 152 (18) ◽  
pp. 703-708 ◽  
Author(s):  
Gábor László Kovács ◽  
Judit Dénes ◽  
Erika Hubina ◽  
László Kovács ◽  
Sándor Czirják ◽  
...  

The Acromegaly Consensus Group redefined the consensus criteria for cure of acromegaly. 74 neurosurgeons and experienced endocrinologists summarized the latest results on diagnosis and treatment of acromegaly. In this consensus statement the reliable growth hormone and insulin-like growth factor-1 assays were established. Definition of disease control was discussed based on the available publications and evidence. This short communication summarizes the clinical aspects of consensus criteria for diagnosis and cure of acromegaly based on the original article. Orv. Hetil., 2011, 152, 703–708.


Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1559-P
Author(s):  
JANET K. SNELL-BERGEON ◽  
JANE E.B. REUSCH ◽  
AMY D. BAUMGARTNER ◽  
MELANIE CREE-GREEN ◽  
KRISTEN J. NADEAU

Sign in / Sign up

Export Citation Format

Share Document